
Multiple Sclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Multiple Sclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Multiple Sclerosis - Drugs In Development, 2022, provides an overview of the Multiple Sclerosis (Central Nervous System) pipeline landscape.
Multiple sclerosis (MS) is a potentially debilitating disease in which body's immune system eats away at the protective sheath (myelin) that covers nerves. Damage to myelin causes interference in the communication between brain, spinal cord and other areas of body. Symptoms include numbness or weakness in one or more limbs, double vision or blurring of vision, tingling or pain in parts of body, fatigue and slurred speech. The predisposing factors include age, gender, family history and certain infections.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Multiple Sclerosis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Multiple Sclerosis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Multiple Sclerosis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Multiple Sclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 2, 23, 28, 50, 4, 203, 51 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 42 and 1 molecules, respectively.
Multiple Sclerosis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Multiple Sclerosis - Drugs In Development, 2022, provides an overview of the Multiple Sclerosis (Central Nervous System) pipeline landscape.
Multiple sclerosis (MS) is a potentially debilitating disease in which body's immune system eats away at the protective sheath (myelin) that covers nerves. Damage to myelin causes interference in the communication between brain, spinal cord and other areas of body. Symptoms include numbness or weakness in one or more limbs, double vision or blurring of vision, tingling or pain in parts of body, fatigue and slurred speech. The predisposing factors include age, gender, family history and certain infections.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Multiple Sclerosis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Multiple Sclerosis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Multiple Sclerosis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Multiple Sclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 2, 23, 28, 50, 4, 203, 51 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 42 and 1 molecules, respectively.
Multiple Sclerosis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Multiple Sclerosis (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Multiple Sclerosis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Multiple Sclerosis (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Multiple Sclerosis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Multiple Sclerosis (Central Nervous System)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Multiple Sclerosis (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Multiple Sclerosis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
672 Pages
- Introduction
- Global Markets Direct Report Coverage
- Multiple Sclerosis – Overview
- Multiple Sclerosis – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Multiple Sclerosis – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Multiple Sclerosis – Companies Involved in Therapeutics Development
- 4D Pharma Plc
- AB Science SA
- Abata Therapeutics
- AbbVie Inc
- Abion Inc
- Abivax SA
- Aditxt Inc
- Aequus Pharmaceuticals Inc
- Affectis Pharmaceuticals AG
- AgoneX Biopharmaceuticals Inc
- Ahead Therapeutics SL
- Akaal Pharma Pty Ltd
- Alector Inc
- Alexion Pharmaceuticals Inc
- Alpha Cancer Technologies Inc
- Alpine Immune Sciences Inc
- Altheia Science SRL
- Amarna Therapeutics BV
- Amgen Inc
- Amylyx Pharmaceuticals Inc
- Ankar Pharma SL
- Anokion SA
- Antisense Therapeutics Ltd
- AnTolRx Inc
- Apaxen
- Aphios Corp
- Apimeds Inc
- AptaTargets SL
- Artax Biopharma Inc
- ArunA Bio Inc
- Asdera LLC
- Aslan Pharmaceuticals Ltd
- Atara Biotherapeutics Inc
- Athersys Inc
- Autobahn Therapeutics Inc
- Autoimmunity Biologic Solutions Inc
- Avicanna Inc
- Avidea Technologies Inc
- Avotres Inc
- Axxam SpA
- Barricade Therapeutics Corp
- Bayer AG
- Baylx Inc
- BioApex sro
- Bioasis Technologies Inc
- Biocad
- Biocon Ltd
- Biocure Technology Inc
- Biogen Inc
- BioIncept LLC
- Bionorica SE
- BioNTech SE
- BioSyngen Pte Ltd
- Biovista Inc
- BioXpress Therapeutics SA
- Bisichem Co Ltd
- Bolder Biotechnology Inc
- Boston Pharmaceuticals Inc
- BoYen Therapeutics Inc
- BrainStorm Cell Therapeutics Inc
- Bridge Biotherapeutics Inc
- Bristol-Myers Squibb Co
- BTB Pharma AB
- CarthroniX Inc
- CavoGene LifeSciences
- Cellerys AG
- Cellix Bio Pvt Ltd
- Cerion LLC
- CGeneTech (Suzhou China) Co Ltd
- Cinnagen Co
- Clene Inc
- Complement Pharma BV
- Compugen Ltd
- Convelo Therapeutics Inc
- Cresence AS
- CSPC Pharmaceutical Group Ltd
- CuraVac Inc
- CuroNZ Ltd
- Cytodyn Inc
- Cyxone AB
- DC4U BV
- Denali Therapeutics Inc
- DiNonA Inc
- Disarm Therapeutics Inc
- Dr. Reddy's Laboratories Ltd
- Dragonfly Therapeutics Inc
- Dualogics Corp
- EA Pharma Co Ltd
- Eikonoklastes Therapeutics Inc
- Eldrug SA
- Eli Lilly and Co
- ENCEFA
- Endece LLC
- Epitracker Inc
- Erganeo
- Ever Supreme Bio Technology Co Ltd
- Evgen Pharma Plc
- Evopoint Bioscience Co Ltd
- F. Hoffmann-La Roche Ltd
- f5 Therapeutics Inc
- Farmacija d.o.o. Tuzla
- FibroGenesis LLC
- Find Therapeutics Inc
- Fortuna Fix Inc
- Frequency Therapeutics Inc
- FSD Pharma Inc
- GABA Therapeutics Inc
- Galmed Pharmaceuticals Ltd
- Genentech USA Inc
- Generos Biomedical Technology (Hangzhou) Co Ltd
- Genervon Biopharmaceuticals LLC
- GeNeuro SA
- Gilead Sciences Inc
- Glialogix Inc
- Glixogen Therapeutics
- Gossamer Bio Inc
- GSK plc
- Guangzhou BeBetter Medicine Technology Co Ltd
- Guangzhou Lupeng Pharmaceutical Co Ltd
- H. Lundbeck AS
- Hope Biosciences LLC
- HuniLife Biotechnology Inc
- iCell Gene Therapeutics LLC
- Idorsia Pharmaceutical Ltd
- Iltoo Pharma
- ImCyse SA
- Immune Response BioPharma Inc
- Immungenetics AG
- Immunic Inc
- ImmunoBiome Inc
- ImmunoChem Therapeutics LLC
- Immunwork Inc
- ImmusanT Inc
- Immutep Ltd
- Impetis Biosciences Ltd
- Imstem Biotechnology Inc
- InFlectis BioScience SAS
- Inmagene Biopharmaceuticals Ltd
- Inmune Bio Inc
- InnoBioscience LLC
- InnoCare Pharma Ltd
- Innovimmune Biotherapeutics Inc
- Io Therapeutics Inc
- ISOThrive Inc
- Istesso Ltd
- J2H Biotech
- Johnson & Johnson
- JSR Life Sciences LLC
- Jura Bio Inc
- Jyant Technologies Inc
- Karo Pharma AB
- Klogene Therapeutics Inc
- Kogenix Therapeutics Inc
- Kymera Therapeutics Inc
- Kyorin Pharmaceutical Co Ltd
- Landos Biopharma Inc
- Lead Discovery Center GmbH
- Leukosight Inc
- LFB SA
- LIFNano Rx Ltd
- Lys Therapeutics SAS
- Mabion SA
- MAKScientific LLC
- Malachite Innovations Inc
- Mapi Pharma Ltd
- Maruho Co Ltd
- MD Healthcare Inc
- Med-Life Discoveries LP
- MedAnnex Ltd
- MedDay SA
- Medsenic SAS
- Mercaptor Discoveries Inc
- Merck & Co Inc
- Merck KGaA
- MetiMedi Pharmaceuticals Co Ltd
- MetrioPharm AG
- Millennium Pharmaceuticals Inc
- Mitochon Pharmaceuticals Inc
- Mitotech SA
- Mitsubishi Tanabe Pharma Corp
- MMJ International Holdings Corp
- Mochida Pharmaceutical Co Ltd
- Moderna Inc
- Molecules For Health Inc
- MorphoSys AG
- MyMD Pharmaceuticals Inc
- Nanjing Aimeifei Biomedical Technology Co Ltd
- NervGen Pharma Corp
- Neuraly Inc
- Neuren Pharmaceuticals Ltd
- Neuro Vigor LLC
- NeuroGenesis Ltd
- NeuroScientific Biopharmaceuticals Ltd
- New World Laboratories Inc
- Novartis AG
- Novellus Therapeutics Ltd
- Novoron Bioscience Inc
- Numab Therapeutics AG
- Oculis SA
- Omeros Corp
- Oncodesign SA
- Op-T-Mune Inc
- Orion Biotechnology Canada Ltd
- Orpheris Inc
- Oryzon Genomics SA
- OSE Immunotherapeutics SA
- Ossianix Inc
- Pahan Therapeutics
- Palisade Bio, Inc
- Pangen Biotech Inc
- Par'Immune SAS
- Parkside Scientific Inc
- Parvus Therapeutics Inc
- Pasithea Therapeutics Corp
- PB Immune Therapeutics Co Ltd
- PharmatrophiX Inc
- PharmCADD Co Ltd
- Pheno Therapeutics Ltd
- Pipeline Therapeutics Inc
- Polpharma Biologics SA
- PolTREG SA
- PrecisemAb Biotech Co Ltd
- Principia Biopharma Inc
- Progenitor Therapeutics Ltd
- ProNoxis AB
- Protheragen Inc
- Provid Pharmaceuticals Inc
- Q Therapeutics Inc
- Quimatryx SL
- ReceptoPharm Inc
- RegeneRx Biopharmaceuticals Inc
- Rekover Therapeutics Ltd
- RemeGen Co Ltd
- ReNetX Bio
- ReNeuroGen LLC
- Resverlogix Corp
- Revalesio Corp
- Reven Holdings Inc
- Rewind Therapeutics NV
- Rigel Pharmaceuticals Inc
- Riptide Bioscience Inc
- Sana Biotechnology Inc
- SanBio Co Ltd
- Sangamo Therapeutics Inc
- Sanofi
- Sansho Co Ltd
- Santhera Pharmaceuticals Holding AG
- Sarepta Therapeutics Inc
- Sareum Holdings Plc
- Scientus Pharma Inc
- Score Pharma Inc
- Senda Biosciences Inc
- Senzer Ltd
- Serenity Bioworks Inc
- Shanghai Pharmaceutical Group Co Ltd
- Shanxi Zhendong Pharmaceutical Co Ltd
- Shenzhen Chipscreen Biosciences Co Ltd
- Silo Pharma Inc
- SinoCelltech Group Ltd
- Sironax Ltd
- Sorrento Therapeutics Inc
- Statera Biopharma Inc
- Stem Cell Medicine Ltd
- Sujana Biotech, LLC
- Suzhou Connect Biopharmaceuticals Ltd
- SynAct Pharma AB
- Synaptogenix Inc
- Takeda Pharmaceutical Co Ltd
- Tavanta Therapeutics Inc
- Teikoku Pharma USA Inc
- TeraImmune Inc
- Tetra Therapeutics
- Tevogen Bio Inc
- Theratome Bio Inc
- Therini Bio Inc
- Tiziana Life Sciences Plc
- TolerogenixX GmbH
- Tonix Pharmaceuticals Holding Corp
- Transparency Life Sciences LLC
- Travecta Therapeutics Pte Ltd
- Trio Medicines Ltd
- Twinpigbiolab Co Ltd
- TwotoBiotech Ltd
- UBI Pharma Inc
- UCB SA
- USA Elixiria Biotech Inc
- Vaccinex Inc
- Vascular Biogenics Ltd
- Vertex Pharmaceuticals Inc
- Vir Biotechnology Inc
- Virogenomics BioDevelopment Inc
- Virtici LLC
- Vitalis LLC
- Vitro Biopharma Inc
- Voronoi Group
- West Lake Biomedical Technology (Hangzhou) Co Ltd
- Worg Pharmaceuticals Hangzhou Co Ltd
- Xalud Therapeutics Inc
- Xonovo Inc
- XOStem Biosciences Ltd
- Zydus Lifesciences Ltd
- ZyVersa Therapeutics Inc
- Multiple Sclerosis – Drug Profiles
- (aspirin + dimethyl fumarate) – Drug Profile
- (aspirin + diroximel fumarate) – Drug Profile
- (aspirin + monomethyl fumarate) – Drug Profile
- (cannabidiol + dronabinol) – Drug Profile
- (metenkefalin + tridecactide) – Drug Profile
- (sodium phenylbutyrate + taurursodiol) – Drug Profile
- 12 Programs – Drug Profile
- 2-CCPA – Drug Profile
- AB-126 – Drug Profile
- abivertinib maleate – Drug Profile
- ABX-002 – Drug Profile
- acazicolcept – Drug Profile
- ACT-10041239 – Drug Profile
- ACT-101 – Drug Profile
- ACY-738 – Drug Profile
- AFC-5128 – Drug Profile
- AK-119 – Drug Profile
- aldesleukin – Drug Profile
- alemtuzumab biosimilar – Drug Profile
- AlloRx Stem Cell therapy – Drug Profile
- AMA-003 – Drug Profile
- Amilo-5MER – Drug Profile
- amiselimod hydrochloride – Drug Profile
- ANK-700 – Drug Profile
- Annexuzlimab – Drug Profile
- AP-1 – Drug Profile
- APH-1403 – Drug Profile
- ApTOLL – Drug Profile
- AQS-1304 – Drug Profile
- arsenic trioxide 1 – Drug Profile
- ASD-005 – Drug Profile
- AT-1226 – Drug Profile
- ATA-188 – Drug Profile
- ATL-1102 – Drug Profile
- Autoimmune Diseases – Drug Profile
- AVCN-319302 – Drug Profile
- AVT-001 – Drug Profile
- AX-007 – Drug Profile
- AX-024 – Drug Profile
- AXER-204 – Drug Profile
- B-001 – Drug Profile
- BA-1521 – Drug Profile
- BBT-032 – Drug Profile
- BBT-401 – Drug Profile
- bee venom – Drug Profile
- belimumab – Drug Profile
- BG-002 – Drug Profile
- BIIB-061 – Drug Profile
- BIIB-091 – Drug Profile
- BIIB-100 – Drug Profile
- BIIB-107 – Drug Profile
- biotin – Drug Profile
- BMS-986196 – Drug Profile
- BOS-172767 – Drug Profile
- Bryostatin-1 – Drug Profile
- BSC-3301 – Drug Profile
- BTB-001 – Drug Profile
- BVA-101 – Drug Profile
- BVX-20 – Drug Profile
- BXU-001 – Drug Profile
- BY-102 – Drug Profile
- CBP-307 – Drug Profile
- Cell Therapy for Autoimmune Disorders, Cardiovascular Disorders, CNS Disorders, Infectious Disease, Musculoskeletal Disorders and Oncology – Drug Profile
- Cell Therapy for Central Nervous System Disorders – Drug Profile
- Cell Therapy for Neurology and Infectious Disease – Drug Profile
- Cellular Immunotherapy for Central Nervous System Disorders – Drug Profile
- Cellular Immunotherapy for Epstein-Barr Viral Infections, Multiple Sclerosis and Systemic Lupus Erythematosus – Drug Profile
- Cellular Immunotherapy for Multiple Sclerosis – Drug Profile
- Cellular Immunotherapy for Oncology and Neurology – Drug Profile
- Cellular Immunotherapy for Pemphigus Vulgaris – Drug Profile
- Cerium dioxide – Drug Profile
- CGEN-15001 – Drug Profile
- CHEC-9 – Drug Profile
- cinnabarinic acid – Drug Profile
- CLS-12311 – Drug Profile
- CLXNEU-06 – Drug Profile
- CNMAU-8 – Drug Profile
- CRES-102 – Drug Profile
- CS-12192 – Drug Profile
- CYMS-101 – Drug Profile
- dapirolizumab pegol – Drug Profile
- debamestrocel – Drug Profile
- deuterated etifoxine – Drug Profile
- didox – Drug Profile
- dimethyl fumarate DR – Drug Profile
- diroximel fumarate DR – Drug Profile
- divozilimab – Drug Profile
- DLA-001 – Drug Profile
- DNL-788 – Drug Profile
- DNP-007 – Drug Profile
- dronabinol – Drug Profile
- Drug to Agonize ER-Beta for Multiple Sclerosis – Drug Profile
- Drugs to Antagonize gp130 for Metastatic Cancer and Multiple Sclerosis – Drug Profile
- DUOC-01 – Drug Profile
- EGF1-48 – Drug Profile
- ELB-00824 – Drug Profile
- elezanumab – Drug Profile
- Elmyelin – Drug Profile
- Emtin-B – Drug Profile
- Engineered Exosomes 2 – Drug Profile
- ET-101 – Drug Profile
- ETI-059 – Drug Profile
- etifoxine – Drug Profile
- evobrutinib – Drug Profile
- farudodstat – Drug Profile
- fenebrutinib – Drug Profile
- foralumab – Drug Profile
- FR-104 – Drug Profile
- FREQ-162 – Drug Profile
- frexalimab – Drug Profile
- FSDC-10 – Drug Profile
- FTX-101 – Drug Profile
- Fusion Protein for Allergic Asthma, Multiple Sclerosis and Transplant Rejection – Drug Profile
- Fusion Protein for Multiple Sclerosis – Drug Profile
- Fusion Protein to Activate Del-1 for Multiple Sclerosis and Periodontitis – Drug Profile
- Fusion Protein to Target ASGPR for Multiple Sclerosis – Drug Profile
- G-Gpep – Drug Profile
- GB-7208 – Drug Profile
- GEA-284 – Drug Profile
- Gene Therapies for Multiple Sclerosis and Type 1 Diabetes – Drug Profile
- Gene Therapy for Multiple Sclerosis – Drug Profile
- Gene Therapy for Primary Progressive Multiple Sclerosis (PPMS) and Systemic Lupus Erythematosus – Drug Profile
- Gene Therapy to Activate CD274 for Multiple Sclerosis – Drug Profile
- Gene Therapy to Activate IL23R for Multiple Sclerosis – Drug Profile
- Gene Therapy to Activate KL for Multiple Sclerosis – Drug Profile
- Gene Therapy to Target BCMA and CD19 for Blood Cancers and Systemic lupus erythematosus – Drug Profile
- Gene Therapy to Target IL-10, NT-3 and LINGO-1 for Central Nervous System Disorders – Drug Profile
- Gene-Modified Cell Therapy for Primary Progressive Multiple Sclerosis and Secondary Progressive Multiple Sclerosis – Drug Profile
- glatiramer acetate ER – Drug Profile
- Glunozumab – Drug Profile
- GM-607 – Drug Profile
- GPR174 – Drug Profile
- GSK-247246 – Drug Profile
- GSK-3888130 – Drug Profile
- histamine dihydrochloride – Drug Profile
- HuL-001 – Drug Profile
- HYCO-13 – Drug Profile
- hydralazine hydrochloride – Drug Profile
- IB-MS – Drug Profile
- ibudilast – Drug Profile
- IC-100 – Drug Profile
- IFB-048 – Drug Profile
- IL7R-005 – Drug Profile
- IMB-002 – Drug Profile
- IMCY-0141 – Drug Profile
- IMG-004 – Drug Profile
- IMP-761 – Drug Profile
- IMS-001 – Drug Profile
- IMS-002 – Drug Profile
- interferon beta – Drug Profile
- interferon beta biobetter – Drug Profile
- interferon beta-1b – Drug Profile
- INV-17 – Drug Profile
- INV-88 – Drug Profile
- invimestrocel – Drug Profile
- IPG-002 – Drug Profile
- IPG-011 – Drug Profile
- IPG-1094 – Drug Profile
- IR-902 – Drug Profile
- IRX-4204 – Drug Profile
- ISOT-101 – Drug Profile
- IST-3 – Drug Profile
- ITIT-03 – Drug Profile
- ixazomib citrate – Drug Profile
- J2H-1801 – Drug Profile
- JM-4 – Drug Profile
- JT-06 – Drug Profile
- KB-3944 – Drug Profile
- Kesimpta – Drug Profile
- KGYY-15 – Drug Profile
- KTX-201 – Drug Profile
- LABP-111 – Drug Profile
- LABP-66 – Drug Profile
- Lemtrada – Drug Profile
- leronlimab – Drug Profile
- lisinopril – Drug Profile
- LLL-12 – Drug Profile
- LM-22A4 – Drug Profile
- LN-001 – Drug Profile
- LP-168 – Drug Profile
- LP-169 – Drug Profile
- Lu-AG22515 – Drug Profile
- LUCID-21302 – Drug Profile
- MAK-1400 – Drug Profile
- masitinib – Drug Profile
- MCC-950 – Drug Profile
- MD-011 – Drug Profile
- MD-056 – Drug Profile
- MDH-101 – Drug Profile
- MDH-204 – Drug Profile
- METI-101 – Drug Profile
- METI-204 – Drug Profile
- MIC-Lx – Drug Profile
- mitoxantrone hydrochloride – Drug Profile
- MK-7110 – Drug Profile
- Monoclonal Antibodies for Multiple Sclerosis and Neuroinflammation – Drug Profile
- Monoclonal Antibodies to Inhibit ITGAM for Glomerulonephritis, Inflammation, Multiple Sclerosis, Thrombosis and Vascular Disorders – Drug Profile
- Monoclonal Antibodies to Inhibit Plexin-B1 and Sema4D for Oncology, Neurology and Metabolic Disorders – Drug Profile
- Monoclonal Antibody for Autoimmune Diseases – Drug Profile
- Monoclonal Antibody to Inhibit CD6 for Autoimmune Uveitis and Multiple Sclerosis – Drug Profile
- Monoclonal Antibody to Inhibit ELTD1 for Glioblastoma Multiforme and Multiple Sclerosis – Drug Profile
- Monoclonal Antibody to Inhibit GM-CSF for Autoimmune Disorders, Immunology and Pulmonary Disease – Drug Profile
- Monoclonal Antibody to Inhibit IL12B for Multiple Sclerosis and Rheumatoid Arthritis – Drug Profile
- Monoclonal Antibody to Inhibit IL1B for Multiple Sclerosis – Drug Profile
- Monoclonal Antibody to Target Fibrin for Alzheimer's Disease and Multiple Sclerosis – Drug Profile
- MP-101 – Drug Profile
- MP-1032 – Drug Profile
- MPEPK-011 – Drug Profile
- mRNA-1195 – Drug Profile
- MRx-0002 – Drug Profile
- MW-151 – Drug Profile
- MW-189 – Drug Profile
- MyMD-1 – Drug Profile
- nabiximols – Drug Profile
- nalfurafine – Drug Profile
- naltrexone hydrochloride – Drug Profile
- natalizumab – Drug Profile
- natalizumab biosimilar – Drug Profile
- NCB-8 – Drug Profile
- ND-007 – Drug Profile
- ND-646 – Drug Profile
- NDC-1308 – Drug Profile
- NG-1 – Drug Profile
- NG-2 – Drug Profile
- NLY-001 – Drug Profile
- NNZ-2591 – Drug Profile
- NOVO-117 – Drug Profile
- NOVO-118 – Drug Profile
- NRP-2945 – Drug Profile
- NSI-777 – Drug Profile
- NV-002 – Drug Profile
- NVG-291 – Drug Profile
- NVG-291R – Drug Profile
- NWL-283 – Drug Profile
- NYU-007 – Drug Profile
- OB-002 – Drug Profile
- OB-002M – Drug Profile
- obefazimod – Drug Profile
- OCHNCNP-1 – Drug Profile
- ocrelizumab – Drug Profile
- ocrelizumab biosimilar – Drug Profile
- OCS-05 – Drug Profile
- ODS-101 – Drug Profile
- ofatumumab – Drug Profile
- Oligonucleotide to Inhibit IL-17A for Multiple Sclerosis – Drug Profile
- OP-329 – Drug Profile
- OP-330 – Drug Profile
- OP-401 – Drug Profile
- orelabrutinib – Drug Profile
- OSX-110 – Drug Profile
- P2X7 – Drug Profile
- PAT-102 – Drug Profile
- PB-101 – Drug Profile
- PB-301 – Drug Profile
- PCD-201 – Drug Profile
- pecazine – Drug Profile
- peginterferon beta-1a – Drug Profile
- pegipanermin – Drug Profile
- pepinemab – Drug Profile
- Peptide to Agonize Galanin Receptor 1,2,3 for IBD and CNS Disorders – Drug Profile
- Peptides to Inhibit MAPK14 and MAPK11 for Multiple Sclerosis, Pancreatic Cancer Rheumatoid Arthritis – Drug Profile
- PIPE-307 – Drug Profile
- pirlindole – Drug Profile
- Plastomitin – Drug Profile
- ponesimod – Drug Profile
- PPI-1025 – Drug Profile
- Preimplantation Factor – Drug Profile
- PSA-20 – Drug Profile
- psilocybin – Drug Profile
- PTG-007 – Drug Profile
- PV-267 – Drug Profile
- Q-Cells – Drug Profile
- QTX-125 – Drug Profile
- QTX-153 – Drug Profile
- R-491 – Drug Profile
- R-835 – Drug Profile
- ravulizumab LA – Drug Profile
- Recombinant Peptide for Multiple Sclerosis – Drug Profile
- Recombinant Protein for Inflammatory Bowel Disease, Multiple Sclerosis and Psoriasis – Drug Profile
- Recombinant Protein for Multiple Sclerosis – Drug Profile
- remibrutinib – Drug Profile
- resomelagon – Drug Profile
- RG-6035 – Drug Profile
- RGN-352 – Drug Profile
- rituximab biosimilar – Drug Profile
- RNS-60 – Drug Profile
- RP-182 – Drug Profile
- RPCN-1003a – Drug Profile
- RPI-78M – Drug Profile
- RTL-551 – Drug Profile
- RVX-297 – Drug Profile
- SAR-20347 – Drug Profile
- SB-618 – Drug Profile
- SC-379 – Drug Profile
- SCM-010 – Drug Profile
- SCT-300 – Drug Profile
- SDC-1801 – Drug Profile
- SER-101 – Drug Profile
- SFX-01 – Drug Profile
- siponimod fumarate – Drug Profile
- SIR-2446 – Drug Profile
- Small Molecule for Multiple Sclerosis – Drug Profile
- Small Molecule to Activate NFE2L2 for Central Nervous System, Metabolic Disorders, Cardiovascular and Ophthalmology – Drug Profile
- Small Molecule to Antagonize GPR17 for Central Nervous System Disorders – Drug Profile
- Small Molecule to Block CRAC Channel for Multiple Sclerosis – Drug Profile
- Small Molecule to Inhibit Autotaxin for Central Nervous System and Gastrointestinal Disorders – Drug Profile
- Small Molecule to Inhibit C6 for Multiple Sclerosis – Drug Profile
- Small Molecule to Inhibit Myeloperoxidase for Central Nervous System Disorders, Multiple Sclerosis and Sickle Cell Disease – Drug Profile
- Small Molecule to Inhibit PDE4B for Multiple Sclerosis and Rheumatoid Arthritis – Drug Profile
- Small Molecule to Inhibit PI3K Gamma for Multiple Sclerosis – Drug Profile
- Small Molecules for Alzheimer's Disease and Multiple Sclerosis – Drug Profile
- Small Molecules for Central Nervous System Disorders – Drug Profile
- Small Molecules for Dermatology, Immunology, Metabolic and CNS Disorders – Drug Profile
- Small Molecules for Multiple Sclerosis – Drug Profile
- Small Molecules to Activate NOX2 for Autoimmune Diseases – Drug Profile
- Small Molecules to Agonize CB1 and CB2 for Central Nervous System Disorders – Drug Profile
- Small Molecules to Agonize ESR2 for Multiple Sclerosis – Drug Profile
- Small Molecules to Antagonize GP130 for Multiple Sclerosis – Drug Profile
- Small Molecules to Antagonize RORC for Immunology, Multiple Sclerosis and Non-Alcoholic Steatohepatis – Drug Profile
- Small Molecules to Antagonize RORC for Psoriasis, Multiple Sclerosis And Ulcerative Colitis – Drug Profile
- Small Molecules to Block Kv1.3 for Autoimmune Disorders – Drug Profile
- Small Molecules to Block Kv1.3 Ion Channel for Multiple Sclerosis, Immunology, Inflammatory Bowel Disease and Type 1 Diabetes – Drug Profile
- Small Molecules to Inhibit BMP for Multiple Sclerosis – Drug Profile
- Small Molecules to Inhibit Emopamil Binding Protein for Multiple Sclerosis – Drug Profile
- Small Molecules to Inhibit GLI1 for Multiple Sclerosis – Drug Profile
- Small Molecules to Inhibit Hyaluronidase for Multiple Sclerosis – Drug Profile
- Small Molecules to Inhibit MIF for Multiple Sclerosis and Rheumatoid Arthritis – Drug Profile
- Small Molecules to Inhibit SARM1 for Neurology and Glaucoma – Drug Profile
- Small Molecules to Inhibit STAT3 for Multiple Sclerosis – Drug Profile
- smderpept – Drug Profile
- SPI-0300 – Drug Profile
- SPU-16 – Drug Profile
- ST-968 – Drug Profile
- Stem Cell Therapy for Multiple Sclerosis – Drug Profile
- sulfasalazine – Drug Profile
- SVT-201 – Drug Profile
- SYNCAV-4 – Drug Profile
- Synthetic Peptide for Neurological and Psychiatric Diseases – Drug Profile
- Synthetic Peptide to Inhibit GAPDH for Ischemic Stroke and Multiple Sclerosis – Drug Profile
- Synthetic Peptides to Inhibit DRB1 for Multiple Sclerosis – Drug Profile
- Synthetic Peptides to Inhibit T-Cell Receptor for Multiple Sclerosis – Drug Profile
- T-20K – Drug Profile
- TAK-828 – Drug Profile
- TAVT-124 – Drug Profile
- TDP-101 – Drug Profile
- TE-5126 – Drug Profile
- TE-5232 – Drug Profile
- telitacicept – Drug Profile
- temelimab – Drug Profile
- tenofovir alafenamide – Drug Profile
- teriflunomide – Drug Profile
- TFM-735 – Drug Profile
- Thera-101 – Drug Profile
- TI-235 – Drug Profile
- TM-5484 – Drug Profile
- TNX-1500 – Drug Profile
- tolebrutinib – Drug Profile
- TPU-012 – Drug Profile
- TR-8 – Drug Profile
- TVT-004 – Drug Profile
- TVT-074 – Drug Profile
- TVT-094 – Drug Profile
- TVT-134 – Drug Profile
- TVT-244 – Drug Profile
- UB-552 – Drug Profile
- ublituximab – Drug Profile
- UMSC-01 – Drug Profile
- unasnemab – Drug Profile
- Vaccine for Autoimmune Diseases and Multiple Sclerosis – Drug Profile
- Vaccine for Immunology and Oncology – Drug Profile
- Vaccine for Multiple Sclerosis – Drug Profile
- vafidemstat – Drug Profile
- vamorolone – Drug Profile
- VB-601 – Drug Profile
- vidofludimus calcium – Drug Profile
- VISTA-Ig – Drug Profile
- VRN-042 – Drug Profile
- VTCMS-3 – Drug Profile
- VX-5 – Drug Profile
- WEHI-345 – Drug Profile
- WP-1303 – Drug Profile
- Xacrel – Drug Profile
- XB-3004 – Drug Profile
- XN-001 – Drug Profile
- XNW-1011 – Drug Profile
- XT-101 – Drug Profile
- XT-150 – Drug Profile
- YHHU-4952 – Drug Profile
- ZD-03 – Drug Profile
- ZK-824859 – Drug Profile
- ZXBT-1158 – Drug Profile
- ZYIL-1 – Drug Profile
- Multiple Sclerosis – Dormant Projects
- Multiple Sclerosis – Discontinued Products
- Multiple Sclerosis – Product Development Milestones
- Featured News & Press Releases
- Dec 31, 2025: Immunic provides update on vidofludimus calcium clinical trials
- Nov 17, 2022: Immunic reports new data from phase 2 EMPhASIS trial of vidofludimus calcium in relapsing-remitting multiple sclerosis supporting the drug's neuroprotective potential
- Nov 14, 2022: NervGen Pharma completes dosing in its third multiple ascending dose cohort in phase 1 clinical trial of NVG-291
- Nov 10, 2022: Tiziana Life Sciences announces near-term strategic focus on intranasal foralumab for diseases of the central nervous system (CNS)
- Nov 02, 2022: Tiziana Life Sciences completes enrollment of the first patient cohort for its intermediate-size patient population expanded access program to evaluate foralumab in non-active secondary multiple sclerosis patients
- Oct 28, 2022: Genentech to present new Ocrevus (ocrelizumab) data in multiple sclerosis and continued research into neuromyelitis optica spectrum disorder at ECTRIMS 2022
- Oct 28, 2022: GeNeuro’s ProTEct-MS phase 2 trial data, presented at the ECTRIMS 2022 Congress in Amsterdam, confirms synergistic neuroprotective potential of Temelimab in MS
- Oct 28, 2022: NervGen pharma presenting at Upcoming Scientific Meetings
- Oct 27, 2022: The Karolinska Institutet’s Academic Specialist Center (ASC) to present results of GeNeuro’s ProTEct-MS phase 2 study of Temelimab at ECTRIMS 2022
- Oct 26, 2022: Tiziana Life Sciences starts enrollment of the first patient cohort in its intermediate size patient population expanded access program to evaluate foralumab in non-active secondary multiple sclerosis patients
- Oct 26, 2022: TG Therapeutics announces presentation of exploratory analyses from the ULTIMATE I & II phase 3 trials of ublituximab in multiple sclerosis presented at the 2022 European Committee for treatment and research in multiple sclerosis
- Oct 26, 2022: Cyxone presents T20K program at the ECTRIMS conference
- Oct 26, 2022: Merck highlights new data for evobrutinib, first BTKi to demonstrate sustained clinical benefit for people with RMS through three and a half years of treatment
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Table 1: Number of Products under Development for Multiple Sclerosis, 2022
- Table 2: Number of Products under Development by Companies, 2022
- Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
- Table 4: Number of Products under Development by Companies, 2022 (Contd..2)
- Table 5: Number of Products under Development by Companies, 2022 (Contd..3)
- Table 6: Number of Products under Development by Companies, 2022 (Contd..4)
- Table 7: Number of Products under Development by Companies, 2022 (Contd..5)
- Table 8: Number of Products under Development by Companies, 2022 (Contd..6)
- Table 9: Number of Products under Development by Companies, 2022 (Contd..7)
- Table 10: Number of Products under Development by Companies, 2022 (Contd..8)
- Table 11: Number of Products under Development by Companies, 2022 (Contd..9)
- Table 12: Number of Products under Development by Companies, 2022 (Contd..10)
- Table 13: Number of Products under Development by Companies, 2022 (Contd..11)
- Table 14: Number of Products under Development by Companies, 2022 (Contd..12)
- Table 15: Number of Products under Development by Companies, 2022 (Contd..13)
- Table 16: Number of Products under Development by Companies, 2022 (Contd..14)
- Table 17: Number of Products under Development by Companies, 2022 (Contd..15)
- Table 18: Number of Products under Development by Universities/Institutes, 2022
- Table 19: Number of Products under Development by Universities/Institutes, 2022 (Contd..1)
- Table 20: Number of Products under Development by Universities/Institutes, 2022 (Contd..2)
- Table 21: Products under Development by Companies, 2022
- Table 22: Products under Development by Companies, 2022 (Contd..1)
- Table 23: Products under Development by Companies, 2022 (Contd..2)
- Table 24: Products under Development by Companies, 2022 (Contd..3)
- Table 25: Products under Development by Companies, 2022 (Contd..4)
- Table 26: Products under Development by Companies, 2022 (Contd..5)
- Table 27: Products under Development by Companies, 2022 (Contd..6)
- Table 28: Products under Development by Companies, 2022 (Contd..7)
- Table 29: Products under Development by Companies, 2022 (Contd..8)
- Table 30: Products under Development by Companies, 2022 (Contd..9)
- Table 31: Products under Development by Companies, 2022 (Contd..10)
- Table 32: Products under Development by Companies, 2022 (Contd..11)
- Table 33: Products under Development by Companies, 2022 (Contd..12)
- Table 34: Products under Development by Companies, 2022 (Contd..13)
- Table 35: Products under Development by Companies, 2022 (Contd..14)
- Table 36: Products under Development by Companies, 2022 (Contd..15)
- Table 37: Products under Development by Companies, 2022 (Contd..16)
- Table 38: Products under Development by Companies, 2022 (Contd..17)
- Table 39: Products under Development by Companies, 2022 (Contd..18)
- Table 40: Products under Development by Companies, 2022 (Contd..19)
- Table 41: Products under Development by Companies, 2022 (Contd..20)
- Table 42: Products under Development by Companies, 2022 (Contd..21)
- Table 43: Products under Development by Companies, 2022 (Contd..22)
- Table 44: Products under Development by Companies, 2022 (C
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.